Summary

• Page properties (2 modified, 0 added, 0 removed)

Details

Page properties

Tags

...	...	@@ -1,1 +1,1 @@
1		-US:SRNE
	1	+US:SRNE|USA|GB:0L85

Content

...	...	@@ -19,7 +19,7 @@
19	19
20	20	**Sorrento Successfully Completes Phase 1 Study, an Oral Treatment and Prevention of COVID-19** {{footnote}}https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-successfully-completes-phase-1-study-and-proceeding{{/footnote}}
21	21
22		-Oct. 17, 2022; Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster. The study done on n 58 healthy volunteers.
	22	+Oct. 17, 2022; Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster. The study done on 58 healthy volunteers.
23	23
24	24
25	25	A phase 1 trial in participants infected with SARS-CoV-2 has been initiated in China (MPR-COV-101CN), and a total 56 participants will be enrolled to assess the safety, tolerability, and efficacy in 3 MAD dose cohorts (300 mg BID, 600 mg BID and 800 mg BID daily for 7.5 days). Eight participants infected with SARS-CoV-2 in the first MAD dose cohort of 300 mg BID have been dosed.
...	...	@@ -105,13 +105,17 @@
105	105
106	106	== Company History ==
107	107
108		-|2013|(((
	108	+
	109	+(% style="width:921px" %)
	110	+|(% style="width:66px" %)**Year**|(% style="width:854px" %)**Milestone**
	111	+|(% style="width:66px" %)2009|(% style="width:854px" %)Founded
	112	+|(% style="width:66px" %)2013|(% style="width:854px" %)(((
109	109	Acquired Resiniferatoxin (RTX) assets via the acquisition of Sherrington Pharmaceuticals Inc.
110	110
111	111	Acquired Antibody Drug Conjugation (ADC) technologies via acquisition of Concortis Biosystems Corp.
112	112	)))
113		-|2014|Out-licensed PD-L1 for Greater China market to Lee’s Pharm
114		-|2016|(((
	117	+|(% style="width:66px" %)2014|(% style="width:854px" %)Out-licensed PD-L1 for Greater China market to Lee’s Pharm
	118	+|(% style="width:66px" %)2016|(% style="width:854px" %)(((
115	115	Formed ImmuneOncia JV with Yuhan Pharmaceuticals
116	116
117	117	Acquired ZTlido® via majority stake in Scilex Pharmaceuticals
...	...	@@ -120,18 +120,18 @@
120	120
121	121	Formed Levena Suzhou Biopharma Co. LTD for Antibody Drug Conjugation (ADC) services
122	122	)))
123		-|2017|(((
	127	+|(% style="width:66px" %)2017|(% style="width:854px" %)(((
124	124	Acquired Oncolytic Virus platform via the acquisition of Virttu Biologics Limited
125	125
126	126	Formed Celularity with Celgene and United Therapeutics
127	127	)))
128		-|2018|Acquired Sofusa® Lymphatic Delivery System from Kimberly-Clark
129		-|2019|(((
	132	+|(% style="width:66px" %)2018|(% style="width:854px" %)Acquired Sofusa® Lymphatic Delivery System from Kimberly-Clark
	133	+|(% style="width:66px" %)2019|(% style="width:854px" %)(((
130	130	Acquired Semnur Pharmaceuticals
131	131
132	132	Formed Scilex Holding to consolidate the merger of Scilex Pharma and Semnur Pharma
133	133	)))
134		-|2020|(((
	138	+|(% style="width:66px" %)2020|(% style="width:854px" %)(((
135	135	Exclusively licensed Abivertinib from ACEA Therapeutics for all indications worldwide, excluding China
136	136
137	137	Exclusively licensed HP-LAMP diagnostic platform from Columbia University for the detection of coronaviruses and influenza viruses
...	...	@@ -138,9 +138,10 @@
138	138
139	139	Acquired SmartPharm Therapeutics
140	140	)))
141		-|2021|Acquired ACEA Therapeutics
142		-|2022|Acquired Virexhealth
	145	+|(% style="width:66px" %)2021|(% style="width:854px" %)Acquired ACEA Therapeutics
	146	+|(% style="width:66px" %)2022|(% style="width:854px" %)Acquired Virexhealth
143	143
	148	+
144	144	= References =
145	145
146	146	{{putFootnotes/}}